A comparison of cholestyramine and nicotinic acid in the treatment of familial type II hyperlipoproteinaemia.
1 The effects of cholestyramine and nicotinic acid on plasma lipid concentration have been compared in patients with type IIa hyperlipoproteinaemia. 2 During a 3-month period, cholestyramine resulted in a mean decrease in cholesterol levels of 26%. Triglyceride levels rose in eight of the ten patients during treatment with this drug but in the majority of patients remained within the normal range. 3 During nicotinic acid therapy, cholesterol fell by a mean of 21% and triglyceride by a mean of 23%. 4 The slow release preparation of nicotinic acid used was acceptable to the majority of the patients studied and the results therefore suggest that this drug may be a useful alternative to the more widely used agent, cholestyramine.
D000293:Adolescent; D000328:Adult; D002648:Child; D002784:Cholesterol / Q000097:blood; D002792:Cholestyramine Resin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy*; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy* / Q000235:genetics*; D008077:Lipoproteins, LDL / Q000097:blood*; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D009539:Nicotinic Acids / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
D008077:Lipoproteins, LDL; D009539:Nicotinic Acids; D014280:Triglycerides; D002792:Cholestyramine Resin; D002784:Cholesterol